Sernova Biotherapeutics Inc · TSX:SVA

Sernova Biotherapeutics — Sernova — Investor Presentation (May 2020)

33 slides from Sernova Biotherapeutics's investor presentation, May 2020

  1. Slide 1: The Path To A Regenerative Medicine Cure

    Slide 1: The Path To A Regenerative Medicine Cure

    SEOVF TRADED ON The Path To A Regenerative Medicine Cure Corporate Presentation May 2020

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expects

  3. Slide 3: Regenerative Medicine - The Future Now

    Slide 3: Regenerative Medicine - The Future Now

    Regenerative Medicine - The Future Now Regenerative Medicine (RM) is a rapidly evolving field of science developing new therapeutic solutions to treat disease:  with the repair or growth of new tissues & organs, i.e. organ regeneration  repairing cells at the gene level to prevent disease, i.e. ge

  4. Slide 4: Sernova: Innovator & Leader

    Slide 4: Sernova: Innovator & Leader

    Sernova: Innovator & Leader Publicly traded, clinical-stage RM therapeutics solution innovator & leader:  Cell therapy therapeutics solution platform treating chronic diseases & enhancing daily QOL  Integrated RM therapeutic solution (implantable Cell Pouch™ device + immune-protected therapeutic c

  5. Slide 5: Sernova's Platform Approach

    Slide 5: Sernova's Platform Approach

    Sernova's Platform Approach Integrated RM Therapeutic Solution for 28% 40% Treatment of Chronic Diseases 32% Cell Pouch Therapeutic Cells Immune Protection Implantable proprietary medical Human cells (donor / stem) & Technologies to protect device that provides vascularized tissues that produce & re

  6. Slide 6: Worldwide IP / Patent Portfolio

    Slide 6: Worldwide IP / Patent Portfolio

    Worldwide IP / Patent Portfolio International patents & patent applications portfolio in multiple patent families with broad application & continued expansion:  Composition & use of medical devices for delivery & cell transplantation  Glucose responsive insulin secreting stem cell technologies  L

  7. Slide 7: Diabetes … Finally Hope for a Functional Cure

    Slide 7: Diabetes … Finally Hope for a Functional Cure

    Diabetes … Finally Hope for a Functional Cure The Reality: Diabetes is one of the most prevalent diseases & pervasive medical problems impacting society & everyday quality of life (QOL) today  463 million affected worldwide and nearly 10% of these individuals have T1D(1)  T1D represents a potentia

  8. Slide 8: Sernova Pipeline

    Slide 8: Sernova Pipeline

    Sernova Pipeline CELL POUCH PRE- DEVELOPMENT CANDIDATE CLINICAL PHASE I PHASE II PHASE III STAGE INDICATION HUMAN DONOR ISLETS, P H A S E I /I I I N I T I AT E D HYPOGLYCEMIA SYSTEMIC IMMUNE DEC 2018 UNAWARENESS PROTECTION T1D A N T I C I PAT E D 2 ND ALL INSULIN LOCALLY IMMUNE- A P P R O VA L F O R

  9. Slide 9: Diabetes Market Opportunities for Sernova

    Slide 9: Diabetes Market Opportunities for Sernova

    Diabetes Market Opportunities for Sernova IP Status 2020 Potential Patient Population Potential Commercial Opportunity (before market access considerations) T1D Severe HU T1D Severe HU Device / Method T1D Severe HU All T1D T1D Severe HU All T1D with Human with Human Patent with iPSC with iPSC with i

  10. Slide 10: RM Diabetes Competitive Landscape

    Slide 10: RM Diabetes Competitive Landscape

    RM Diabetes Competitive Landscape Clinical Efficacy Data: Device Vascularization Local Immune Financial Metrics Therapeutic C-peptide Levels Islet Engraftment Protection Technology (USD Millions) Measured in Bloodstream Demonstrated in Humans Phase I/II initiated late 2018 in T1D Interim data demons

  11. Slide 11: Cell Pouch Solves Device Conundrum

    Slide 11: Cell Pouch Solves Device Conundrum

    Cell Pouch Solves Device Conundrum The Device Conundrum “We thought the cells would be the hard part and focused our efforts there. It’s obvious now having a functional device will be the limiting factor and there are few current options.” Big Pharma executive 2020 JPM comment The challenging device

  12. Slide 12: Therapeutic Cells

    Slide 12: Therapeutic Cells

    Therapeutic Cells Therapeutic Cell Options  Human donor cells enable early safety / efficacy testing in the clinic for indications & patients with unmet needs & advanced disease (i.e. diabetes HU patients). Supply is limited; however, they enable Cell Pouch validation in preparation for stem cell t

  13. Slide 13: Immune Protection

    Slide 13: Immune Protection

    Immune Protection  Transplanted therapeutic cells must be protected from a natural immune system attack response.  While established systemic transplantation immuno-suppression (anti-rejection) drugs can be effective, local immune protection (LIP) is optimal. LIP alternatives present different opp

  14. Slide 14: Biologically Compatible Delivery Process

    Slide 14: Biologically Compatible Delivery Process

    Biologically Compatible Delivery Process Cell Pouch Implantation & Therapeutic Cells Delivery Process Proprietary Cell Pouch is Therapeutics cells are Therapeutic cells release placed deep under the skin, transplanted directly into the missing proteins or allowing for vascularization & vascularized

  15. Slide 15: Strategic Development Approach

    Slide 15: Strategic Development Approach

    Strategic Development Approach Device Therapeutic Immune Sernova Integrated Cells Protection RM Therapeutic Solution Immuno Portfolio Human Suppression Drugs Cell Therapeutic Donor (systemic) Pouch Cells Sernova Stem Cell Cell Encapsulation Proprietary Derived Conformal Coating Cell Pouch (iPSC / EP

  16. Slide 16: Diabetes Clinical Progress Summary

    Slide 16: Diabetes Clinical Progress Summary

    Diabetes Clinical Progress Summary  Completion of first-in-human proof-of-concept study for diabetic condition HU  Clinical protocol & regulatory package development for US Ph I / II clinical trial for Pre 2018 diabetic HU condition (T1D Study)  FDA IND clearance to commence T1D Study  T1D Study

  17. Slide 17: T1D First Clinical Indication: HU

    Slide 17: T1D First Clinical Indication: HU

    T1D First Clinical Indication: HU Hypoglycemia Hypoglycemia unawareness unawareness (HU), the(HU), most the most critical critical unmet needunmet needaffects in diabetes, in diabetes, 15% of T1D affects patients 15% (~240K of T1Dinpatients patients (~240 K patients in the US alone) the US alone) 

  18. Slide 18: US Ph I/II Study Design

    Slide 18: US Ph I/II Study Design

    US Ph I/II Study Design US Ph I/II Safety, Tolerability, Efficacy Study Study Design: Company-sponsored IND. Open-label, single-arm study. Human donor islets are transplanted into the Cell Pouch after implantation & stable anti-rejection medication activity has been established. Primary Objective: T

  19. Slide 19: US Ph I/II Study Design

    Slide 19: US Ph I/II Study Design

    US Ph I/II Study Design US Ph I/II Safety, Tolerability, Efficacy Study Immuno Secondary Endpoints: Suppression Survival of Endocrine Tissue & Identification of Hormones Introduced Small Reduction in hypoglycemic events (sentinel) Reduction in HbA1c Pouches Cell 1st Islet Dose Removed Pouch™ Transpl

  20. Slide 20: US Ph I/II: Case Study Early Findings

    Slide 20: US Ph I/II: Case Study Early Findings

    US Ph I/II: Case Study Early Findings US Ph I/II Safety, Tolerability, Efficacy Study Safety Findings (90 days post-transplant) Incidence & severity of adverse events associated with Cell Pouch were monitored:  No incidences of AEs determined to be probable or highly probable to the Cell Pouch  Ce

  21. Slide 21: US Ph I/II: Case Study Early Findings

    Slide 21: US Ph I/II: Case Study Early Findings

    US Ph I/II: Case Study Early Findings US Ph I/II Safety, Tolerability, Efficacy Study First Patient Observed Data Presented by Clinical Investigator* Early Efficacy Findings Islet Transplant Status: Before 3 Mo. After 90-day post-transplant glucose tolerance test (i.e. patient given a high sugar dri

  22. Slide 22: US Ph I/II: Case Study Early Findings

    Slide 22: US Ph I/II: Case Study Early Findings

    US Ph I/II: Case Study Early Findings Improvement in ALL CGM Parameters Blood Glucose Over Time (mg/dL) Baseline: More excursions seen pre-transplant Parameter Baseline Post-transplant (90 days) High Glucose Value (mg/dL) 285 231 Low Glucose Value (mg/dL) 50 66* # Glucose Excursions 15 3 # High Excu

  23. Slide 23: US Ph I/II: 90-Days Post Transplant

    Slide 23: US Ph I/II: 90-Days Post Transplant

    US Ph I/II: 90-Days Post Transplant Achievement of Secondary Endpoint “Survival of endocrine tissue in the Cell Pouch™ (defined by positive staining of islets during histological analysis) [ Time Frame: 90±5 days post-transplant for sentinel Cell Pouch™ ]” Islets Independent Pathologist reported: 

  24. Slide 24: Earlier First-in-Human Study

    Slide 24: Earlier First-in-Human Study

    Earlier First-in-Human Study First-in-World Successful Proof-of-Concept Study Design  T1D subjects with HU & a history of severe hypoglycemic episodes  Open-label, single-arm  Donor islet transplantation 2 – 24 weeks post Cell Pouch implantation  Primary Endpoint: Safety post Cell Pouch implanta

  25. Slide 25: T1D Data: Pre-Clinical Studies

    Slide 25: T1D Data: Pre-Clinical Studies

    T1D Data: Pre-Clinical Studies Clinical Studies Human Study #2: US Ph I/II Safety, Human Study #1: First-in-Human Study #2: US Ph I/II Safety, Tolerability, Efficacy Study Proof-of-Concept Tolerability, 2019 • Conducted in conjunction with the University of • Conducted in conjunction with Health Can

  26. Slide 26: Cell Pouch – A Durable Cell Environment

    Slide 26: Cell Pouch – A Durable Cell Environment

    Cell Pouch – A Durable Cell Environment Long-Term Vascularized Tissue Chamber Development Proven Across All Pre-Clinical 1) Animal Models, 2) Implant Sites & 3) Disease Models 1 2 3H&E 1.7x Non-Transplanted Cell Pouch Hemophilia A Mouse Abdomen mouse model Model (NHP) Sernova Confidential SH1-P047 N

  27. Slide 27: Pre-Clinical Diabetes Model Efficacy

    Slide 27: Pre-Clinical Diabetes Model Efficacy

    Pre-Clinical Diabetes Model Efficacy Pre-Clinical Porcine Large Animal Cell Pouch Study Cell Pouch Implant Pancreatectomy Diabetes Islet Transplant Cell Pouch Removal Induction (STZ) 4-8 weeks 1 day 4-7 days 8-12 weeks 1 week Insulin Insulin 12 Weeks Post Cell Pouch Nuclei Glucagon WHY IS THIS and I

  28. Slide 28: Hemophilia A Program

    Slide 28: Hemophilia A Program

    Hemophilia A Program Estimated  ~20 K patients across North America & EU Market  ~$10 B orphan indication Benefits of Sernova’s Cell Pouch with factor VIII releasing cells:  Patients receive regular infusions of missing Standard clotting factors (i.e. factor VIII)  Reduce / eliminate factor of C

  29. Slide 29: Hemophilia A Program: Pre-Clinical Success

    Slide 29: Hemophilia A Program: Pre-Clinical Success

    Hemophilia A Program: Pre-Clinical Success Pre-Clinical Safety & Efficacy of Hemophilia Cell Therapy in the Cell Pouch Confirmed Release-tested HLA-ABC BOECs FVIII DAPI Human stained (red) 40x Cell Pouch Transplanted with Cells Human corrected Human factor VIII BOECs transplanted corrected blood 40×

  30. Slide 30: Thyroid Disease Program

    Slide 30: Thyroid Disease Program

    Thyroid Disease Program Estimated  150,000 thyroidectomies performed annually in US  ~$2.2 B market opportunity Market Benefits of Sernova’s Cell Pouch with Thyroid releasing cells:  Patients require lifelong thyroid hormone  Reduce / eliminate daily life replacement therapy Standard long thyroi

  31. Slide 31: Thyroid Program: Pre-Clinical Success

    Slide 31: Thyroid Program: Pre-Clinical Success

    Thyroid Program: Pre-Clinical Success Pre-Clinical Safety & Efficacy of the Thyroid Tissue Therapy in the Cell Pouch Human Thyroid Tissue Surviving Human Thyroid Tissue in Cell Pouch in mouse model ( 3 months post-transplant) Cell Pouch Transplanted with Healthy Human TG (green) TPO (red) Thyroid Ti

  32. Slide 32: NEXT STEPS - 2020 Action Plan

    Slide 32: NEXT STEPS - 2020 Action Plan

    NEXT STEPS - 2020 Action Plan  Acquire or license local immune-protection technologies for therapeutic cells Platform  Advance local immune-protected diabetes stem cell technology in preparation Technology for First-in-Man (FIM) study  Expand existing strong worldwide multi-family patent portfoli

  33. Slide 33: 700 Collip Circle, Suite 114 London, Ontario Canada

    Slide 33: 700 Collip Circle, Suite 114 London, Ontario Canada

    700 Collip Circle, Suite 114 London, Ontario Canada N6G 4X8 (519) 858-5126 info@sernova.com www.sernova.com

Source: Internet Archive copy of sernova.com

More decks from Sernova Biotherapeutics Inc

All 29 Sernova Biotherapeutics decks